CBDual Biotechnology Corp. Announces the Completion of their New Clinical Trial Center in Southern California

CBDual Biotechnology Corp. (“CBDUAL”) announced today the completion of the company’s new clinical trial center in Southern California.

CBDual’s new facility provides patients with easy access to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual will develop protocols to improve patient safety and data integrity in clinical research trials in compliance with the HIPAA.

The first scheduled trial will study the medicinal and therapeutic effects of CBD on oral health. The study anticipates between 1,000-2,000 patients and will test the effects of different CBD based mouthwashes and toothpastes.

CBDual has recently entered into a cross licensing agreement with Cavitation Technologies, Inc (OTCQB: CVAT; Berlin: WTC). This agreement covers intellectual property involving the application of technology and patented processes to produce high quality pharmaceutical grade cannabis materials with increased bio-availability and increased shelf life.

Dr. Greg Rubin, CEO of CBDual Biotechnology Corp., previously commented, “The improvement of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. The impact of the new clinical research brings us one step closer to introducing our new products to the US markets.”

Recent breakthroughs in Cannabinoid (CBD) therapies and orally administered products prompt strong forecast for 2017. The Hemp Business Journal estimated that the CBD market will emerge as a $2.1 billion market in consumer sales by 2020. That represents a 700% increase from 2016. According to the National Institute on Drug Abuse, a number of studies have shown that CBD is a non-psychoactive cannabinoid and has a wide range of medical benefits, such as anti- inflammatory and anti-oxidant and many other health related benefits.

About CBDual Biotechnology Corp

CBDual Biotechnology is a privately held; US based Biotechnology Company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquartered in California with its R&D capability in Israel and Ukraine..

Website: http://www.cbdual.com/

About Cavitation Technologies, Inc.

Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement, water treatment and cannabidiol processing. As an add-on to its existing neutralization systems, the company’s patented Nano Reactor™ allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.

Website: http://www.ctinanotech.com/
Follow us on Twitter: https://twitter.com/ctinanotech
Like us on Facebook: https://www.facebook.com/ctinanotech

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.